Immune System News and Research

RSS

New heating therapy reduces mastectomies, kills large tumors

A new treatment developed and tested by University of Oklahoma researchers not only killed large breast cancer tumors, but reduced the need for mastectomies by almost 90 percent. The latest results appear in an upcoming issue of the Annals of Surgical Oncology.

20 Jan 2010

Scientists discover Ebola's immune evasion strategies

A research team led by Gaya Amarasinghe, an assistant professor of biochemistry, biophysics and molecular biology, had previously solved the structure of a critical part of an Ebola protein known as VP35, which is involved in host immune suppression.

20 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

From BD (Becton, Dickinson and Company) 20 Jan 2010

Media outlets examine efforts to develop malaria vaccines

Scientists have identified a group of proteins they say could form the basis of a malaria vaccine, Australia's ABC News reports. "However, they say more laboratory work and clinical trials need to be done, with a vaccine at least 10 years away," the news service reports (Macey, 1/19).

20 Jan 2010

National Institutes of Mental Health awards $8M for HIV research

A multidisciplinary research team at the Johns Hopkins University School of Medicine has been awarded $8 million in funding by the National Institutes of Mental Health to develop methods to rid the body of HIV.

20 Jan 2010

New research at Rhode Island Hospital identifies a treatment for glioblastomas

New research at Rhode Island Hospital has identified a treatment in animal models for glioblastomas - deadly brain tumors which, once diagnosed, offer a poor prognosis and relatively short life expectancy.

20 Jan 2010

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."

20 Jan 2010

Repeated exposure to tobacco smoke makes lung cancer much worse

Repeated exposure to tobacco smoke makes lung cancer much worse, and one reason is that it steps up inflammation in the lung. Scientists at the University of California, San Diego School of Medicine have found that mice with early lung cancer lesions that were repeatedly exposed to tobacco smoke developed larger tumors - and developed tumors more quickly - than unexposed animals.

19 Jan 2010

New findings support the development of vaccine against malaria

Walter and Eliza Hall Institute researchers have uncovered a group of proteins that could form the basis of an effective vaccine against malaria.

19 Jan 2010

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

Results from a study of more than 90,000 Italian women published by the Lancet Oncology found that testing for high-risk types of the human papillomavirus (HPV) DNA is significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) alone.

19 Jan 2010

Babraham Institute research may lead to new means of making purified T cells

Research from the Babraham Institute, reported today in the Journal of Experimental Medicine, provides new insights into how our immune system produces T cells, a type of white blood cell that is an essential part of the body's immune surveillance system for fighting infection. The findings pave the way for a new means of making purified T cells, which gets over one of many hurdles faced in the use of T cells in regenerative medicine and transplantations, and in addition will open up new avenues of research and applications in drug and toxicity testing in industry.

18 Jan 2010

Prescription drugs prove effective in managing moderate to severe psoriasis

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

18 Jan 2010

New insights into molecular interaction between probiotics and altered host intestinal ecosystem in IPAA

Total proctocolectomy with ileal J-pouch-anal anastomosis (IPAA) is the surgical treatment of choice for patients with refractory ulcerative colitis (UC). Although the surgery generally cures UC allowing a significant improvement of health-related quality of life, complications can occur after IPAA.

18 Jan 2010

PATH MVI announces collaboration in development of malaria TBV

The PATH Malaria Vaccine Initiative (MVI) today announced a new collaboration to initiate development toward a vaccine that may eventually help eliminate and eradicate malaria. This collaboration with the Johns Hopkins Bloomberg School of Public Health (JHSPH) and the Sabin Vaccine Institute (Sabin) marks MVI's first investment in transmission-blocking vaccines (TBVs). This vaccine approach aims to stop the malaria parasite from developing in the mosquito, effectively blocking transmission of malaria from mosquitoes to humans. Malaria kills nearly 900,000 people per year, most of them children younger than age five.

18 Jan 2010

A comprehensive overview of stress from neurolobiological and immunological perspective

Stress is one of the most frequently used 'buzz words' across Western societies with an array of meanings ranging from scientifically defined experimental conditions for laboratory animals to a casual word for a nuisance.

18 Jan 2010

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes.

18 Jan 2010

Researchers discover how cells flatten out as they adhere to internal bodily surfaces

Researchers at the University of Illinois at Chicago College of Medicine have discovered how cells in the body flatten out as they adhere to internal bodily surfaces, the first step in a wide range of important processes including clot formation, immune defense, wound healing, and the spread of cancer cells.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

Immune System News and Research

New heating therapy reduces mastectomies, kills large tumors

Scientists discover Ebola's immune evasion strategies

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

JDRF and BD join to develop novel insulin delivery products for treatment of type 1 diabetes

Media outlets examine efforts to develop malaria vaccines

National Institutes of Mental Health awards $8M for HIV research

New research at Rhode Island Hospital identifies a treatment for glioblastomas

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Repeated exposure to tobacco smoke makes lung cancer much worse

New findings support the development of vaccine against malaria

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

Babraham Institute research may lead to new means of making purified T cells

Prescription drugs prove effective in managing moderate to severe psoriasis

New insights into molecular interaction between probiotics and altered host intestinal ecosystem in IPAA

PATH MVI announces collaboration in development of malaria TBV

A comprehensive overview of stress from neurolobiological and immunological perspective

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

Researchers discover how cells flatten out as they adhere to internal bodily surfaces

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News